Vnitr Lek 2013, 59(3):231-233

Treatment of diabetic macular oedema in a type 1 diabetes patient - mistakes in interdisciplinary collaboration

M. Veith
Oftalmologická klinika 3. lékařské fakulty UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Pavel Kuchynka, CSc.

Diabetic retinopathy (DR) is a significant microvascular complication of diabetes. High quality interdisciplinary collaboration is an important aspect of a successful DR therapy. A case of a 41-year-old diabetic is presented below, who has been in our care for almost four years. His Diabetes ID card only contains his current glycaemia values. Although the patient had been regularly given a report for his diabetologist with a request for additional information, we have only obtained one value of glycated haemoglobin through the course of the patient's dispensarisation. For this reason, and the non-stabilisation of DR, we have recommended that the patient starts to see a different diabetologist.

Keywords: diabetic retinopathy; interdisciplinary collaboration

Received: January 24, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Veith M. Treatment of diabetic macular oedema in a type 1 diabetes patient - mistakes in interdisciplinary collaboration. Vnitr Lek. 2013;59(3):231-233.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arevalo JF, Sanchez JG, Wu L et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116; 2009: 1488-1497. Go to original source... Go to PubMed...
    2. Arevalo JF, Lasave AF, Wu L et al. Intravitreal Bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema.: Results of the Pan-American Collaborative Retina Study Group at 24 Months. Retina 2013; 33: 403-413. Go to original source... Go to PubMed...
    3. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695-702. Go to original source... Go to PubMed...
    4. Bandello F, Berchicci L, La Spina C et al. Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res 2012; 48: (Suppl. 1): 16-20. Go to original source... Go to PubMed...
    5. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008; 53: 139-149. Go to original source... Go to PubMed...
    6. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. Go to original source... Go to PubMed...
    7. Diabetic retinopathy Clinical Research Network. A randomized Trial comparing intravitreal triamcinolone acetionicde and focal/grid photocoagulation for diabetic maculoar edema. Ophthalmology 2008; 115: 1447-1459. Go to original source... Go to PubMed...
    8. Dusová J, Studnička J, Rencová E et al. Triamcinolon v léčbě diabetického makulárního edému - roční výsledky. Čes slov Oftal 2008; 64: 149-152.
    9. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No.1. Arch Ophthalmol 1985; 103: 1796-1806. Go to original source...
    10. Fraser-Bell S, Kaines A, Hykin PG. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 2008; 19: 185-189. Go to original source... Go to PubMed...
    11. Gillies MC, Islam FM, Zhu M et al. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007; 91: 1323-1326. Go to original source... Go to PubMed...
    12. Hauser D, Bukelman A, Pokroy R et al. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008; 28: 825-830. Go to original source... Go to PubMed...
    13. Chew E, Klein M, Ferris F et al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Arch Ophthalmol 1996; 114: 1079-1084. Go to original source... Go to PubMed...
    14. Kalvodová B. Screening diabetické retinopatie v ČR - guideline. Čes slov Oftal 2002; 1: 3-10.
    15. Kang SW, Sa HS, Cho HY et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124: 653-658. Go to original source... Go to PubMed...
    16. Keech AC, Mitchell P, Summanen P et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687-1697. Go to original source... Go to PubMed...
    17. Kim JE, Pollack JS, Miller DG et al. Isis Study Group: ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008; 28: 735-740. Go to original source... Go to PubMed...
    18. Klein R, Klein B, Moss S et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Int Med 1989; 149: 2427-2432. Go to original source...
    19. Klein R, Klein B, Moss E et al. Glycosilated haemoglobin predicts the incidence and progression diabetic retinopathy. JAMA 1988; 260: 2864-2871. Go to original source...
    20. Lam DS, Chan CK, Mohamed S et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007; 91: 199-203. Go to original source... Go to PubMed...
    21. Michaelides M, Kaines A, Hamilton RD et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). Ophthalmology 2010; 117: 1078-1086. Go to original source... Go to PubMed...
    22. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625. Go to original source... Go to PubMed...
    23. Ockrim ZK, Sivaprasad S, Falk S et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 2008; 92: 795-799. Go to original source... Go to PubMed...
    24. Ozkiris A, Evereklioglu C, Erkiliç K et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004; 14: 543-549. Go to original source...
    25. Roth DB, Realini T, Feuer WJ et al. Short-term complications of intravitreal injection of triamcinolone acetonide. Retina 2008; 28: 66-70. Go to original source... Go to PubMed...
    26. Rusňák Š, Fidranská H, Belfínová Š et al. Resopce diabetického cystoidního makulárního edému po intravitreální aplikaci triamcinolon acetonidu v závislosti na kompenzaci základního onemocnění. Čes slov Oftal 2008; 64: 26-29.
    27. Řehák J, Chrapek O, Prachařová Z et al. Naše zkušenosti v léčbě diabetické makulopatie. Čes a slov Oftal 2004; 60: 112-117.
    28. Schmid KE, Neumaier-Ammerer B, Stolba U et al. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 2006; 244: 1446-1152. Go to original source... Go to PubMed...
    29. Sosna T, Švancarová R, Netuková M. Diabetická retinopatie - rizikové faktory, prevence a terapie. Čes a slov Oftal 2010; 66: 195-203.
    30. Sosna T, Švancarová R, Netuková M et al. Současný pohled na diabetický makulární edém. Čes a slov Oftal 2012; 68: 91-97.
    31. Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev 2012; 8: 237-246. Go to original source... Go to PubMed...
    32. Studnička J. Diabetický makulární edém - nové možnosti léčby. Čes a slov Oftal 2012; 68: 61-63.
    33. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Am J Cardiol 2007; 99: (Suppl.): 21-33. Go to original source... Go to PubMed...
    34. UK Prospective Diabetes Study (UKDPS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKDPS 38. BMJ 1998; 317: 703-713. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.